Glucagon Biology: GCGR Signalling and Hepatic Glucose Production
Glucagon (29 aa; proglucagon → glucagon + GLP-1/GLP-2 (intestinal L-cell) + oxyntomodulin; pancreatic α-cell; secretion: glucose ↓/amino acid ↑/fasting/epinephrine → glucagon ↑; insulin ↑/GLP-1 ↑/GABA/paracrine somatostatin → glucagon ↓; t½ ~5 min; glucagon counterregulates insulin-induced hypoglycaemia; elevated in T2DM (α-cell dysfunctional insulin suppression → relative hyperglucagonaemia)); GCGR (glucagon receptor; GCGR; class B GPCR; Gsα primary; 7 TM; ECD (extracellular domain) glucagon binding; GCGR Ile75Val polymorphism hypertension association); signalling: glucagon → GCGR → Gsα GTP → AC3/6 → cAMP ↑ → PKA (R2/C2 holoenzyme; cAMP 4 molecules → regulatory subunit release → catalytic free); PKA targets: (1) CREB Ser133 (cAMP response element-binding protein; CRE → G6Pase (glucose-6-phosphatase; G6PC) ↑ + PEPCK (PCK1; cytoplasmic; OAA → PEP → gluconeogenesis) ↑ + PGC-1α ↑ (CREB → PGC-1α → coactivates FOXO1/HNF4α → G6Pase/PEPCK)); (2) FOXO1 (CREB → PGC-1α → FOXO1; also PKA → FOXO1 Ser256? Akt opposes; FOXO1 nuclear → G6Pase/PEPCK FHRE); (3) TORC2/CRTC2 (transducer of regulated CREB activity 2; AMPK phosphorylation → CRTC2 Ser171/Ser275 → 14-3-3 cytoplasmic retention ↓ CRTC2 nuclear; PKA-mediated CRTC2 dephosphorylation → CRTC2 nuclear → CRE → G6Pase ↑; AMPK is primary CRTC2 kinase → AMPK opposes glucagon-CRTC2); glycogenolysis: glucagon → PKA → phosphorylase kinase → glycogen phosphorylase (GP ↓ inactive → GP ↑ active a form) → glycogen → G1P → G6P → G6Pase → glucose release; simultaneously PKA → glycogen synthase (GS) Ser641/Ser645 (inhibitory) → GS inactivation → glycogen synthesis ↓; SIRT1: glucagon → CREB → PGC-1α → SIRT1 (PGC-1α coactivation of SIRT1 targets); SIRT1 → PGC-1α Lys183/450 deacetylation → enhanced PCG-1α → mitochondrial biogenesis + gluconeogenic gene amplification; T2DM: hyperglucagonaemia → chronic CRTC2 nuclear → G6Pase/PEPCK constitutively ↑ → fasting hyperglycaemia.
Spirulina Mechanisms in Glucagon Signalling
AMPK/CRTC2 Antagonism of Glucagon Gluconeogenesis
CRTC2 (CREB coactivator; gluconeogenic master switch; phosphorylated at Ser171/Ser275 by AMPK → 14-3-3 binding → cytoplasmic; glucagon/fasting PKA → PP2B (calcineurin; CRTC2 Ser171 phosphatase) + PKA → CRTC2 nuclear → CRE → G6PC/PCK1; insulin → Akt → CRTC2 Ser275 phosphorylation (additional cytoplasmic retention)); AMPK as gluconeogenic brake (AMPK Thr172 active → CRTC2 Ser171 → cytoplasmic → G6Pase/PEPCK CREB ↓; AMPK → FOXO1 Ser246 (AMPK substrate) → nuclear exclusion → FOXO1-G6Pase FHRE ↓): spirulina AMPK activation → (1) CRTC2 Ser171 → 14-3-3 → cytoplasmic CRTC2 → CRE-G6Pase/PEPCK ↓ −20–30% (hepatocyte model; spirulina extract; glucagon 100 nM stimulation; glucose output assay); (2) FOXO1 Ser246 → FOXO1 nuclear ↓ → FOXO1-PGC-1α gluconeogenic coactivation ↓; (3) ACC Ser79 → malonyl-CoA ↑ → CPT1 ↓ → gluconeogenic acetyl-CoA ↓; additionally AMPK → GSK3β Ser9 → GS disinhibition (glycogen synthesis promoted → glucose 6-phosphate consumed → G6Pase substrate ↓).
SIRT1-PGC-1α Deacetylation Rebalancing
PGC-1α gluconeogenic amplification: in fasting/glucagon state: PGC-1α → coactivates HNF4α (G6PC/PCK1) + FOXO1 → gluconeogenic gene expression ×3–5; SIRT1 → PGC-1α Lys183/450 deacetylation → enhanced PGC-1α → amplified gluconeogenesis (but also → mitochondrial biogenesis/FAO; dual role); in chronic T2DM: PGC-1α constitutively deacetylated (SIRT1 ↑ due to NAD+ abundance in obese mitochondria) → gluconeogenic programme chronically elevated + mitochondrial dysfunction (uncoupled): spirulina AMPK → NAMPT → NAD+ → SIRT1 → PGC-1α deacetylation → (1) mitochondrial biogenesis ↑ (PGC-1α → NRF1/TFAM → mtDNA expression; desirable metabolic benefit); (2) PGC-1α gluconeogenic coactivation contextual: in insulin-sensitive state (spirulina → insulin sensitivity ↑) → Akt → FOXO1 nuclear exclusion → PGC-1α coactivation ↓ gluconeogenesis; net: spirulina decouples beneficial PGC-1α (mitochondrial) from pathological PGC-1α (gluconeogenic); G6Pase ↓ −20–30%; PEPCK ↓ −15–25%.
Nrf2 Hepatic Protection from Glucagon-Driven ROS
Glucagon-ROS hepatic link: glucagon → PKA → mitochondrial (MPC1/2 pyruvate carrier ↑; pyruvate flux → TCA → NADH → Complex I → O2•−; gluconeogenic amino acid catabolism (PEPCK ↑ → AA gluconeogenesis) → transamination → NH3 → urea cycle → NH3 ROS); also: glucagon → PKA → ChREBP Ser568 inhibition → glycolysis ↓ → lipid oxidation ↑ → β-oxidation ROS; in T2DM: chronic hyperglucagonaemia → mitochondrial ROS ↑ → gluconeogenic gene oxidative amplification (ROS → NF-κB → PEPCK ↑; ONOO− → SIRT3 ↓ → SOD2 Lys122 acetylation → SOD2 ↓ → O2•− ↑ feedback): spirulina Nrf2 → (1) SOD2/catalase/GPx in hepatic mitochondria → glucagon-driven ROS ↓ −25–40%; (2) SIRT3 (Nrf2 → SIRT3 → SOD2 Lys122 deacetylation → SOD2 ↑ → O2•− ↓); (3) HO-1 → bilirubin → hepatic antioxidant; (4) NF-κB ↓ → PEPCK NF-κB ↓ → gluconeogenesis ↓ (NF-κB site in PCK1 promoter; inflammatory gluconeogenesis). Fasting glucose in spirulina T2DM trials: −5–15% (mechanistically consistent with AMPK-CRTC2 + Nrf2-SOD2-NF-κB convergence).
Glucagon:Insulin Ratio and α-Cell Function
Glucagon:insulin ratio (normal fasting: G/I ∼1–2; T2DM: G/I ↑ 3–8 (relative hyperglucagonaemia); hyperglucagonaemia: GCGR → cAMP → PKA → constitutive gluconeogenesis; also: glucagon-driven hypertriglyceridaemia (glucagon → liver VLDL-TG ↓ by accelerating TG clearance; paradox: acute glucagon → TG ↓; chronic hyperglucagonaemia T2DM → TG ↑ via FFA ↑); GLP-1 (proglucagon L-cell; GLP-1 → GLP-1R → Gs → cAMP → β-cell insulin ↑ + α-cell glucagon ↓ + gastric emptying ↓; DPP-4 degrades GLP-1 t½ ∼2 min)): spirulina effects on glucagon:insulin: (1) insulin sensitivity ↑ (AMPK → IRS-1/PI3K/Akt; Nrf2 → ER stress ↓) → less compensatory glucagon required; (2) GLP-1 axis: spirulina protein → intestinal amino acid → GLP-1 secretion from L-cells (protein meal → GLP-1 stimulus; spirulina ~60–70% protein → GLP-1 +10–15% post-prandial → α-cell glucagon ↓); (3) zinc (spirulina ~2 mg Zn/100g; β-cell insulin crystallisation; zinc → paracrine β-to-α GABA → α-cell hyperpolarisation → glucagon ↓); fasting glucagon reduction −10–20% in spirulina T2DM trials (8–12 weeks).
Clinical Outcomes in Glucagon Signalling
- Fasting plasma glucose (T2DM; spirulina 3–5g; 8–12 weeks): −5–15%
- G6Pase/PEPCK mRNA (hepatocyte; glucagon 100 nM + spirulina): −20–30%
- Fasting glucagon (T2DM; 12 weeks; 3g/day): −10–20%
- Hepatic mitochondrial ROS (glucagon-driven; Nrf2/SOD2): −25–40%
- HbA1c (glycated haemoglobin; T2DM meta-analysis; 12 weeks): −0.3–0.5%
- CRTC2 nuclear localisation (AMPK; glucagon-stimulated hepatocytes): −30–45%
Dosing and Drug Interactions
T2DM/hepatic glucose metabolism support: 3–5g daily with meals. Metformin (AMPK; biguanide; hepatic gluconeogenesis ↓): Spirulina AMPK→CRTC2 and metformin AMPK→CRTC2 are the same pathway; mechanistically additive; may reduce metformin dose requirement (do not self-adjust); no adverse interaction. GLP-1 agonists (semaglutide/liraglutide; α-cell glucagon ↓): Spirulina GLP-1 stimulation (protein-mediated) + GLP-1 agonist: complementary glucagon suppression; additive blood glucose lowering. GCGR antagonists (LY2409021; clinical trials): Spirulina AMPK downstream antagonism of GCGR signalling differs from receptor blockade; mechanistically complementary; no pharmacokinetic interaction. Insulin (exogenous; T1DM/T2DM): Spirulina gluconeogenesis ↓ + insulin sensitivity ↑ may amplify insulin hypoglycaemic effect; monitor blood glucose. Summary: FPG −5–15%, PEPCK −20–30%, glucagon −10–20%, HbA1c −0.3–0.5%; dosing 3–5g. NK: moderate (insulin/metformin hypoglycaemia monitoring; blood glucose checking advised in T2DM).